A Phase I Study of CD19 Specific T Cells in CD19 Positive Malignancy
NCT01493453
Terminated
In particular circumstances T cells can be an effective treatment for malignant disease, for example, donor lymphocyte infusions following allogeneic transplants or treatment of EBV related lymphomas post allograft. However, many common cancers are poorly recognised by the immune system in part because of a lack of suitable T cell targets and in part because of defects in antigen presentation by tumours (Garrido, et al 1997). Genetically modified T cells engineered to express chimeric immune rec... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2023
Locations: The Christie NHS Foundation Trust, Manchester, Not set
Conditions: CD19 Positive Non-Hodgkin Lymphoma
Register for Updates
A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome
NCT03899337
Recruiting
The STELLAR trial will assess the effect of acalabrutinib taken in combination with CHOP-R compared to taking CHOP-R alone in patients with newly diagnosed Richter's Syndrome (RS). It will also be a platform to test other new drugs that show potential for treating RS. Chronic lymphocytic Leukaemia (CLL) is the most common blood cancer in adults, usually in their 70s or older. In a few patients, CLL can transform from a slow-growing cancer into an aggressive lymphoma called Richter's Syndrome. RS... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/05/2023
Locations: Belfast City Hospital, Belfast, Not set +15 locations
Conditions: Richter Syndrome
Register for Updates
The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinoma
NCT04262427
Unknown
This is an open label investigator initiated Phase Ib study of combination pembrolizumab (Keytruda), 200mg IV 3 weekly (Q3W) with 50mg oral cyclophosphamide daily (OD) in metastatic renal cell carcinoma patients. 21 patients will be recruited within the United Kingdom (UK) will to examine the efficacy of the combination for up to 35 administrations (2 years). This study will be conducted in compliance with Good Clinical Practice (GCP) and all relevant regulations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/22/2022
Locations: Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, Not set +3 locations
Conditions: Metastatic Renal Cell Carcinoma
Register for Updates
Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity
NCT01265849
Completed
The purpose of this study was to determine whether LI administered in combination with cyclophosphamide, indomethacin and zinc in a multivitamin (CIZ) combination prior to standard of care therapy (surgery followed by radiotherapy or concurrent radiochemotherapy) is safe and will increase the overall survival of subjects with previously untreated locally advanced primary squamous cell carcinoma of the oral cavity or soft palate at a median of 3 to 5 years
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/17/2022
Locations: Simmons Cancer Institute at Southern Illinois University, Springfield, Illinois +101 locations
Conditions: Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Soft Palate
Register for Updates
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
NCT01332968
Completed
This open-label, randomized study will assess the efficacy and safety of obinutuzumab (RO5072759) in combination with chemotherapy compared to rituximab (MabThera/Rituxan) with chemotherapy followed by obinutuzumab or rituximab maintenance in participants with untreated advanced indolent non-Hodgkin's lymphoma. After the end of the induction period, participants achieving response (Complete response \[CR\] or partial response \[PR\]) will undergo a maintenance period continuing on the randomized... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/09/2022
Locations: Highlands Oncology Group, Springdale, Arkansas +182 locations
Conditions: Non-Hodgkin's Lymphoma
Register for Updates
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer
NCT01966471
Completed
This two-arm, randomized, open-label, multicenter study will evaluate the efficacy and safety of trastuzumab emtansine in combination with pertuzumab versus trastuzumab in combination with pertuzumab and a taxane as adjuvant therapy in participants with human epidermal growth (HER) factor 2 (HER2)-positive primary invasive breast cancer. Following surgery and anthracycline-based chemotherapy, participants will receive either trastuzumab emtansine at a dose of 3.6 milligrams per kilogram (mg/kg)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2022
Locations: HonorHealth Research Institute - Bisgrove, Scottsdale, Arizona +294 locations
Conditions: Breast Cancer
Register for Updates
Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma (ALCL 99)
NCT00006455
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective for treating anaplastic large cell lymphoma. PURPOSE: This randomized phase III trial is studying several different regimens of combination chemotherapy to compare how well they work in treating children with anaplastic large cell lymphoma.
Gender:
ALL
Ages:
Between 0 years and 21 years
Trial Updated:
05/24/2022
Locations: St. Anna Children's Hospital, Vienna, Not set +9 locations
Conditions: Lymphoma
Register for Updates
Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy
NCT01679119
Completed
The purpose of this trial is to compare the efficacy and safety of Inotuzumab Ozogamicin in combination with R-CVP with that of R-G-CVP for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) in a population of patients not suitable for anthracycline based chemotherapy. There is no standard of care for the treatment of this group of patients. If demonstrated to be efficacious and safe to deliver this regimen will be further tested in a phase III trial to determine whether this should become... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/17/2022
Locations: Stoke Mandeville Hospital (including Wycombe Hospital), Aylesbury, Not set +39 locations
Conditions: Diffuse Large B Cell Lymphoma
Register for Updates
Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer
NCT02999854
Terminated
The primary objective of this study is to compare safety and efficacy of a haploidentical T-cell depleted HSCT and adjunctive treatment with ATIR101 versus a haploidentical T cell replete HSCT with post-transplant administration of high dose cyclophosphamide (PTCy) in patients with a hematologic malignancy. An additional objective of the study is to compare the effect of the two treatments on quality of life.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/28/2022
Locations: City of Hope National Medical Center, Duarte, California +41 locations
Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Register for Updates
International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma
NCT02066220
Active Not Recruiting
The study PNET 5 MB has been designed for children with medulloblastoma of standard risk (according to the risk-group definitions which have been used so far; e.g. in PNET 4). With the advent of biological parameters for stratification into clinical medulloblastoma trials, the ß-catenin status will be the only criterion according to which study patients will be assigned to either treatment arm PNET 5 MB - LR or to PNET 5 MB - SR, respectively. The initial diagnostic assessments (imaging, staging... Read More
Gender:
ALL
Ages:
Between 3 years and 21 years
Trial Updated:
04/11/2022
Locations: Medical University of Graz, Graz, Not set +76 locations
Conditions: Brain Tumors
Register for Updates
Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma
NCT00637832
Terminated
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiolabeled monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan, can find cancer cells and car... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
12/16/2021
Locations: Christie Hospital, Manchester, England +4 locations
Conditions: Lymphoma
Register for Updates
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
NCT01777152
Completed
This is a double-blind, randomized, multicenter, phase 3 clinical trial to compare the efficacy and safety of brentuximab vedotin in combination with CHP with the standard-of-care CHOP in patients with CD30-positive mature T-cell lymphomas.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2021
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +143 locations
Conditions: Anaplastic Large-Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma
Register for Updates